Guengerich F P, Müller-Enoch D, Blair I A
Mol Pharmacol. 1986 Sep;30(3):287-95.
The anti-arrhythmic quinidine has been reported to be a competitive inhibitor of the catalytic activities of human liver P-450DB, including sparteine delta 2-oxidation and bufuralol 1'-hydroxylation, and we confirmed the observation that submicromolar concentrations are strongly inhibitory. Human liver microsomes oxidize quinidine to the 3-hydroxy (Km 4 microM) and N-oxide (Km 33 microM) products, consonant with in vivo observations. Both bufuralol and sparteine inhibited microsomal quinidine 3-hydroxylation. Liver microsomes prepared from DA strain rats showed a relative deficiency in quinidine 3-hydroxylase activity in females compared to males. These observations might suggest that quinidine oxidation is catalyzed by the same P-450 forms that oxidize debrisoquine, bufuralol, and sparteine; i.e., rat P-450UT-H and P-450DB. However, neither of these two purified enzymes catalyzed quinidine 3-hydroxylation, and anti-P-450UT-H, which strongly inhibits human liver microsomal bufuralol 1'-hydroxylation, did not substantially inhibit quinidine 3-hydroxylation or N-oxygenation. P-450MP, the human S-mephenytoin 4-hydroxylase, also does not appear to oxidize quinidine but P-450NF, the human nifedipine oxidase, does. Anti-P-450NF inhibited greater than 95% of the 3-hydroxylation and greater than 85% of the N-oxygenation of quinidine in several microsomal samples. Quinidine inhibited microsomal nifedipine oxidation and, in a series of human liver samples, rates of nifedipine oxidation were correlated with rates of quinidine oxidation. Thus, quinidine oxidation appears to be catalyzed primarily by P-450NF and not by P-450DB. Quinidine binds 2 orders of magnitude more tightly to P-450DB, which does not oxidize it, than to P-450NF, the major enzyme involved in its oxidation. The substrate specificity of human P-450NF is discussed further in terms of its regioselective oxidations of complex molecules including quinidine, aldrin, benzphetamine, cortisol, testosterone and androstenedione, estradiol, and several 2,6-dimethyl-1,4-dihydropyridines.
据报道,抗心律失常药奎尼丁是人类肝脏P - 450DB催化活性的竞争性抑制剂,包括司巴丁δ2 - 氧化和丁呋洛尔1'- 羟基化,我们证实了亚微摩尔浓度具有强烈抑制作用这一观察结果。人类肝脏微粒体将奎尼丁氧化为3 - 羟基(Km为4 microM)和N - 氧化物(Km为33 microM)产物,这与体内观察结果一致。丁呋洛尔和司巴丁均抑制微粒体奎尼丁3 - 羟基化。与雄性相比,从DA品系大鼠制备的肝脏微粒体在雌性中显示出奎尼丁3 - 羟化酶活性相对不足。这些观察结果可能表明,奎尼丁氧化是由氧化异喹胍、丁呋洛尔和司巴丁的相同P - 450形式催化的;即大鼠P - 450UT - H和P - 450DB。然而,这两种纯化的酶均未催化奎尼丁3 - 羟基化,并且强烈抑制人类肝脏微粒体丁呋洛尔1'- 羟基化的抗P - 450UT - H并未显著抑制奎尼丁3 - 羟基化或N - 氧化。人类S - 美芬妥因4 - 羟化酶P - 450MP似乎也不氧化奎尼丁,但人类硝苯地平氧化酶P - 450NF可以。抗P - 450NF在几个微粒体样品中抑制了大于95%的奎尼丁3 - 羟基化和大于85%的奎尼丁N - 氧化。奎尼丁抑制微粒体硝苯地平氧化,并且在一系列人类肝脏样品中,硝苯地平氧化速率与奎尼丁氧化速率相关。因此,奎尼丁氧化似乎主要由P - 450NF催化,而不是由P - 450DB催化。奎尼丁与不氧化它的P - 450DB的结合比与参与其氧化的主要酶P - 450NF紧密2个数量级。人类P - 450NF的底物特异性将根据其对包括奎尼丁、艾氏剂、苄非他明、皮质醇、睾酮和雄烯二酮、雌二醇以及几种2,6 - 二甲基 - 1,4 - 二氢吡啶在内的复杂分子的区域选择性氧化进行进一步讨论。